Antibiotic resistance in Enterococcus faecium clinical isolates

References

• Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicrob Chemother 2013;68(4):731-42
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41(3):327-33
   PubMed Web of Science ®Google Scholar
• Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012;10(4):266-78
   PubMed Web of Science ®Google Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197(8):1079-81
   PubMed Web of Science ®Google Scholar
• Top J, Willems R, Bonten M. Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen. FEMS Immunol Med Microbiol 2008;52(3):297-308
   PubMedGoogle Scholar
• Rice LB. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc 2012;87(2):198-208
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Gram-positive cocci collected in North American hospitals. 2002Diagn Microbiol Infect Dis 2007;57(4):459-65
   Google Scholar
• Putnam SD, Sader HS, Moet GJ, et al. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens. 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis 2010;67(4):359-68
   PubMedGoogle Scholar
• Bourdon N, Fines-Guyon M, Thiolet JM, et al. Changing trends in vancomycin-resistant enterococci in French hospitals. 2001-08. J Antimicrob Chemother 2011;66(4):713-21
   PubMedGoogle Scholar
• Dowzicky MJ, Chmelarova E. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between. 2004 and 2009. Int J Antimicrob Agents 2011;37(6):562-6
   PubMedGoogle Scholar
• Dowzicky MJ. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between. 2004 and 2009. Clin Ther 2011;33(12):1964-73
   PubMedGoogle Scholar
• Balode A, Punda-Polic V, Dowzicky MJ. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). 2004-2010. Int J Antimicrob Agents 2013;41(6):527-35
   PubMedGoogle Scholar
• Brandon M, Dowzicky MJ. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between. 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol 2013;51(7):2371-8
   PubMedGoogle Scholar
• Sader HS, Flamm RK, Jones RN. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America. and selected countries in the Asia-Pacific Region (2011). Diagn Microbiol Infect Dis 2013;75(4):417-22
   PubMedGoogle Scholar
• Fontana R, Grossato A, Rossi L, et al. Transition from resistance to hypersusceptibility to beta-lactam antibiotics associated with loss of a low-affinity penicillin-binding protein in a Streptococcus faecium mutant highly resistant to penicillin. Antimicrob Agents Chemother 1985;28(5):678-83
   PubMedGoogle Scholar
• Williamson R, le Bouguenec C, Gutmann L, Horaud T. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 1985;131(8):1933-40
   PubMedGoogle Scholar
• Fontana R, Aldegheri M, Ligozzi M, et al. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1994;38(9):1980-3
   PubMedGoogle Scholar
• Mainardi JL, Legrand R, Arthur M, et al. Novel mechanism of beta-lactam resistance due to bypass of D,D-transpeptidation in Enterococcus faecium. J Biol Chem 2000;275(22):16490-6
   PubMedGoogle Scholar
• Mainardi JL, Hugonnet JE, Rusconi F, et al. Unexpected inhibition of peptidoglycan L,D-transpeptidase from Enterococcus faecium by the beta-lactam imipenem. J Biol Chem 2007;282(42):30414-22
   PubMedGoogle Scholar
• Zhang X, Paganelli FL, Bierschenk D, et al. Genome-wide identification of ampicillin resistance determinants in Enterococcus faecium. PLoS Genet 2012;8(6):e1002804
   PubMed Web of Science ®Google Scholar
• Becker B, Cooper MA. Aminoglycoside antibiotics in the 21st century. ACS Chem Biol 2013;8(1):105-15
   PubMed Web of Science ®Google Scholar
• Zembower TR, Noskin GA, Postelnick MJ, et al. The utility of aminoglycosides in an era of emerging drug resistance. Int J Antimicrob Agents 1998;10(2):95-105
   PubMedGoogle Scholar
• Barnes AI, Herrero IL, Albesa I. New aspect of the synergistic antibacterial action of ampicillin and gentamicin. Int J Antimicrob Agents 2005;26(2):146-51
   PubMedGoogle Scholar
• Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000;31(2):586-9
   PubMed Web of Science ®Google Scholar
• Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012;3(5):421-33
   PubMed Web of Science ®Google Scholar
• Costa Y, Galimand M, Leclercq R, et al. Characterization of the chromosomal AAC(6')-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 1993;37(9):1896-903
   PubMed Web of Science ®Google Scholar
• Galimand M, Schmitt E, Panvert M, et al. Intrinsic resistance to aminoglycosides in Enterococcus faecium is conferred by the 16S rRNA m5C1404-specific methyltransferase EfmM. RNA 2011;17(2):251-62
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Available from www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx.
   Google Scholar
• Hidron AI, Edwards JR, Patel J, et al. National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29(11):996-1011
   PubMed Web of Science ®Google Scholar
• Lebreton F, van Schaik W, McGuire AM, et al. Emergence of epidemic multidrug-resistant Enterococcus faecium from animal and commensal strains. MBio 2013;4(4):e00534-13
   PubMed Web of Science ®Google Scholar
• Lester CH, Sandvang D, Olsen SS, et al. Emergence of ampicillin-resistant Enterococcus faecium in Danish hospitals. J Antimicrob Chemother 2008;62(6):1203-6
   PubMedGoogle Scholar
• Werner NL, Hecker MT, Sethi AK, Donskey CJ. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 2011;5(11):187
   Google Scholar
• Galloway-Peña JR, Rice LB, Murray BE. Analysis of. PBP5 of early U.S. isolates of Enterococcus faecium: sequence variation alone does not explain increasing ampicillin resistance over time. Antimicrob Agents Chemother 2011;55(7):3272-7
   PubMedGoogle Scholar
• Galloway-Peña J, Roh JH, Latorre M, et al. Genomic and SNP analyses demonstrate a distant separation of the hospital and community-associated clades of Enterococcus faecium. PLoS ONE 2012;7(1):e30187
   Google Scholar
• Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1(8575-6):57-8
   PubMed Web of Science ®Google Scholar
• Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319(3):157-61
   PubMed Web of Science ®Google Scholar
• Werner G, Coque TM, Hammerum AM, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 2008;13(47): pii : 19046
   Google Scholar
• Gilmore MS, Lebreton F, van Schaik W. Genomic transition of enterococci from gut commensals to leading causes of multidrug-resistant hospital infection in the antibiotic era. Curr Opin Microbiol 2013;16(1):10-16
   PubMed Web of Science ®Google Scholar
• Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008;6(5):637-55
   PubMed Web of Science ®Google Scholar
• Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001;33(2):210-19
   PubMed Web of Science ®Google Scholar
• Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis 2006;42(Suppl 1):S25-34
   PubMedGoogle Scholar
• Hegstad K, Mikalsen T, Coque TM, et al. Mobile genetic elements and their contribution to the emergence of antimicrobial resistant Enterococcus faecalis and Enterococcus faecium. Clin Microbiol Infect 2010;16(6):541-54
   PubMed Web of Science ®Google Scholar
• Watanabe S, Kobayashi N, Quiñones D, et al. Genetic diversity of the low-level vancomycin resistance gene vanC-2/vanC-3 and identification of a novel vanC subtype (vanC-4) in Enterococcus casseliflavus. Microb Drug Resist 2009;15(1):1-9
   PubMedGoogle Scholar
• Lebreton F, Depardieu F, Bourdon N, et al. D-Ala-D-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother 2011;55(10):4606-12
   PubMed Web of Science ®Google Scholar
• Nomura T, Tanimoto K, Shibayama K, et al. Identification of VanN-type vancomycin resistance in an Enterococcus faecium isolate from chicken meat in Japan. Antimicrob Agents Chemother 2012;56(12):6389-92
   PubMedGoogle Scholar
• Cremniter J, Mainardi JL, Josseaume N, et al. Novel mechanism of resistance to glycopeptide antibiotics in Enterococcus faecium. J Biol Chem 2006;281(43):32254-62
   PubMedGoogle Scholar
• Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002;2(9):530-8
   PubMed Web of Science ®Google Scholar
• Leavis HL, Willems RJ, Top J, Bonten MJ. High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J Clin Microbiol 2006;44(3):1059-64
   PubMedGoogle Scholar
• Werner G, Fleige C, Ewert B, et al. High-level ciprofloxacin resistance among hospital-adapted Enterococcus faecium (CC17). Int J Antimicrob Agents 2010;35(2):119-25
   PubMedGoogle Scholar
• Oyamada Y, Ito H, Fujimoto K, et al. Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol 2006;55(Pt 6):729-36
   PubMedGoogle Scholar
• Canu A, Leclercq R. Overcoming bacterial resistance by dual target inhibition: the case of streptogramins. Curr Drug Targets Infect Disord 2001;1(2):215-25
   PubMedGoogle Scholar
• Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997;39(Suppl A):7-13
   Google Scholar
• Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol 2005;3(11):870-81
   PubMed Web of Science ®Google Scholar
• Johnston NJ, Mukhtar TA, Wright GD. Streptogramin antibiotics: mode of action and resistance. Curr Drug Targets 2002;3(4):335-44
   PubMed Web of Science ®Google Scholar
• De Graef EM, Decostere A, De Leener E, et al. Prevalence and mechanism of resistance against macrolides, lincosamides, and streptogramins among Enterococcus faecium isolates from food-producing animals and hospital patients in Belgium. Microb Drug Resist 2007;13(2):135-41
   PubMedGoogle Scholar
• López F, Culebras E, Betriú C, et al. Antimicrobial susceptibility and macrolide resistance genes in Enterococcus faecium with reduced susceptibility to quinupristin-dalfopristin: level of quinupristin-dalfopristin resistance is not dependent on erm(B) attenuator region sequence. Diagn Microbiol Infect Dis 2010;66(1):73-7
   PubMedGoogle Scholar
• Isnard C, Malbruny B, Leclercq R, Cattoir V. Genetic basis for in vitro and in vivo resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP phenotype) in Enterococcus faecium. Antimicrob Agents Chemother 2013;57(9):4463-9
   PubMedGoogle Scholar
• Jackson CR, Fedorka-Cray PJ, Barrett JB, et al. Prevalence of streptogramin resistance in enterococci from animals: identification of vatD from animal sources in the USA. Int J Antimicrob Agents 2007;30(1):60-6
   PubMedGoogle Scholar
• Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005;5(4):209-18
   PubMedGoogle Scholar
• Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003;51(Suppl 2):ii9-16
   Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004;23(2):113-19
   PubMed Web of Science ®Google Scholar
• Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant Gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Am J Infect Control 2007;35(8):521-6
   PubMedGoogle Scholar
• Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe. (2004-2007). Int J Antimicrob Agents 2009;34(2):121-30
   PubMedGoogle Scholar
• Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for. 2007). Diagn Microbiol Infect Dis 2008;62(4):416-26
   PubMed Web of Science ®Google Scholar
• Berenger R, Bourdon N, Auzou M, et al. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between. 2006 and 2008. Med Mal Infect 2011;41(8):405-9
   PubMedGoogle Scholar
• Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39(7):1010-15
   PubMed Web of Science ®Google Scholar
• Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357(9263):1179
   PubMed Web of Science ®Google Scholar
• Seedat J, Zick G, Klare I, et al. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother 2006;50(12):4217-19
   PubMedGoogle Scholar
• Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346(11):867-9
   PubMed Web of Science ®Google Scholar
• Johnson AP, Tysall L, Stockdale MV, et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002;21(10):751-4
   PubMedGoogle Scholar
• Rahim S, Pillai SK, Gold HS, et al. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003;36(11):E146-8
   PubMed Web of Science ®Google Scholar
• Werner G, Bartel M, Wellinghausen N, et al. Detection of mutations conferring resistance to linezolid in Enterococcus spp. by fluorescence in situ hybridization. J Clin Microbiol 2007;45(10):3421-3
   PubMedGoogle Scholar
• Schnitzler P, Schulz K, Lampson C, et al. Molecular analysis of linezolid resistance in clinical Enterococcus faecium isolates by polymerase chain reaction and pyrosequencing. Eur J Clin Microbiol Infect Dis 2011;30(1):121-5
   PubMedGoogle Scholar
• Marshall SH, Donskey CJ, Hutton-Thomas R, et al. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002;46(10):3334-6
   PubMed Web of Science ®Google Scholar
• Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45(7):2154-6
   PubMed Web of Science ®Google Scholar
• Auckland C, Teare L, Cooke F, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002;50(5):743-6
   PubMedGoogle Scholar
• Meka VG, Pillai SK, Sakoulas G, et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004;190(2):311-17
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S, et al. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci. Antimicrob Agents Chemother 2007;51(3):1112-14
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009;63(4):713-15
   PubMedGoogle Scholar
• Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009;53(12):5265-74
   PubMed Web of Science ®Google Scholar
• Locke JB, Hilgers M, Shaw KJ. Mutations in ribosomal protein. L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother 2009;53(12):5275-8
   PubMedGoogle Scholar
• Endimiani A, Blackford M, Dasenbrook EC, et al. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland. Ohio. Antimicrob Agents Chemother 2011;55(4):1684-92
   PubMedGoogle Scholar
• Kehrenberg C, Schwarz S, Jacobsen L, et al. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol Microbiol 2005;57(4):1064-73
   PubMed Web of Science ®Google Scholar
• Schwarz S, Werckenthin C, Kehrenberg C. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob Agents Chemother 2000;44(9):2530-3
   PubMed Web of Science ®Google Scholar
• Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007;64(6):1506-14
   PubMed Web of Science ®Google Scholar
• Diaz L, Kiratisin P, Mendes RE, et al. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012;56(7):3917-22
   PubMed Web of Science ®Google Scholar
• Long KS, Poehlsgaard J, Kehrenberg C, et al. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006;50(7):2500-5
   PubMed Web of Science ®Google Scholar
• Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000;45(6):797-802
   PubMedGoogle Scholar
• Sader HS, Farrell DJ, Jones RN. Antimicrobial activity of daptomycin tested against Gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance. (2003-2009). J Chemother 2011;23(4):200-6
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Corey GR. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 2007;5(2):177-84
   PubMed Web of Science ®Google Scholar
• Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009;64(1):175-80
   PubMedGoogle Scholar
• Crank CW, Scheetz MH, Brielmaier B, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther 2010;32(10):1713-19
   PubMedGoogle Scholar
• Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010;65(6):1126-36
   PubMedGoogle Scholar
• Twilla JD, Finch CK, Usery JB, et al. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J Hosp Med 2012;7(3):243-8
   PubMedGoogle Scholar
• Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45(6):1799-802
   PubMed Web of Science ®Google Scholar
• Lewis JS II, Owens A, Cadena J, et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005;49(4):1664-5
   PubMedGoogle Scholar
• Montero CI, Stock F, Murray PR. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob Agents Chemother 2008;52(3):1167-70
   PubMedGoogle Scholar
• Kelesidis T, Tewhey R, Humphries RM. Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome. J Antimicrob Chemother 2013;68(8):1926-8
   PubMedGoogle Scholar
• Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011;365(10):892-900
   PubMed Web of Science ®Google Scholar
• Munita JM, Panesso D, Diaz L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012;56(8):4354-9
   PubMed Web of Science ®Google Scholar
• Mascher T, Zimmer SL, Smith TA, Helmann JD. Antibiotic-inducible promoter regulated by the cell envelope stress-sensing two-component system LiaRS of Bacillus subtilis. Antimicrob Agents Chemother 2004;48(8):2888-96
   PubMed Web of Science ®Google Scholar
• Wolf D, Kalamorz F, Wecke T, et al. In-depth profiling of the LiaR response of Bacillus subtilis. J Bacteriol 2010;192(18):4680-93
   PubMedGoogle Scholar
• Humphries RM, Kelesidis T, Tewhey R, et al. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012;56(11):6051-3
   PubMedGoogle Scholar
• Tran TT, Panesso D, Gao H, et al. Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 2013;57(1):261-8
   PubMedGoogle Scholar
• Mishra NN, Bayer AS, Tran TT, et al. Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS ONE 2012;7(8):e43958
   PubMed Web of Science ®Google Scholar
• Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007;45(10):1343-6
   PubMedGoogle Scholar
• Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Ann Pharmacother 2008;42(2):289-90
   PubMedGoogle Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14
   PubMed Web of Science ®Google Scholar
• Borbone S, Lupo A, Mezzatesta ML, et al. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants. Int J Antimicrob Agents 2008;31(3):209-15
   PubMedGoogle Scholar
• Rubinstein E, Vaughan D. Tigecycline: a novel glycylcycline. Drugs 2005;65(10):1317-36
   PubMed Web of Science ®Google Scholar
• Aznar J, Lepe JA, Dowzicky MJ. Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study. 2004-2009). J Chemother 2012;24(2):74-80
   PubMed Web of Science ®Google Scholar
• Shen J, Wang Y, Schwarz S. Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 2013;68(8):1697-706
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs 2009;69(7):809-31
   PubMed Web of Science ®Google Scholar
• Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16(6):555-62
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012;10(4):459-73
   PubMed Web of Science ®Google Scholar
• Roux D, Pier GB, Skurnik D. Magic bullets for the 21st century: the reemergence of immunotherapy for multi- and pan-resistant microbes. J Antimicrob Chemother 2012;67(12):2785-7
   PubMed Web of Science ®Google Scholar
• Deresinski S. Bacteriophage therapy: exploiting smaller fleas. Clin Infect Dis 2009;48(8):1096-101
   PubMedGoogle Scholar